CVS Health to provide in-home chemotherapy via CTCA collaboration

CVS Health is working with the Cancer Treatment Centers of America (CTCA) to increase access to chemotherapy at home for eligible, fully insured patients. Together, the companies are focused on minimizing patient exposure to COVID-19 from inpatient or hospital outpatient settings during the pandemic while ensuring continuity of critical cancer care. The program gives patients who may have delayed their care due to COVID-19 the flexibility to receive treatment from home, using Coram’s home infusion capabilities, along with training in chemotherapy administration based on Oncology Nursing Society guidelines, using CTCA’s expertise as a top oncology care provider. In collaboration with CTCA and their approach to quality, safe care, Coram has the ability to reach 97% of the U.S. population, according to the company. The program is being piloted in the Atlanta market and will expand to other areas over the next few months. Clinically eligible and fully insured CTCA patients with a range of cancers will begin their first cycles of infused chemotherapy in the hospital or outpatient care center, and, if tolerated over a number of months, can be transitioned home for continued infusions. Once home, patients will receive in-home Coram nurse visits to administer the therapy, paired with regular telehealth visits with their CTCA clinician and care team.